Table 2 Validations of predicted drug-PPI interactions
Drug Name | Protein #1 (direct binding partner) | Protein #2 (PPI) | Reference |
|---|---|---|---|
Bicalutamide | ABL1 | CASP9 | Danquah et al. Pharm Res. 26(9):2081–92. (2009) [38] |
ABL1 | CCNA2 | Katayama et al. Int J Oncol. 36(3):553–62. (2010) [39] | |
ABL1 | MAPK11 | Malinowska et al. Endocr Relat Cancer. 16:155–169. (2009) [40] | |
Cladribine | ADA | DCK | Sasvári-Székely et al. Biochem Pharmacol. 56(9):1175–1179. (1998) [41] |
Chlordiazepoxide | AKT1 | NR3C1 | Curtin et al. Brain Behav, Immun. 23(4): 535–547. (2009) [42] |
Progeterone | AR | F2 | Oger et al. Arterioscler Thromb Vasc Biol. 23:1671–1676. (2003) [43] |
Cyproterone | AR | CASP3 | Eckle et al. Toxicol Pathol. 32:9–15. (2004) [44] |
AR | NR3C1 | Honer et al. Mol Pharmacol. 63(5):1012–1020. (2003) [45] | |
Telmisasrtan | BCL2 | IL2 | Syrbe et al. Hypertens Res. 30(6):521–527. (2007) [46] |
Sorafenib | BRAF | PRKCQ | Jane et al. J Pharmacol Exp Ther. 319(3):1070–1080. (2006) [47] |
Methotrexate | DHFR | CDK2 | Maddika et al. J Cell Sci. 121:979–988. (2008) [48] |